glulisine

Insulin glulisine is a recombinant human insulin analog created by substituting asparagine with lysine at position B3 and lysine with glutamic acid at position B29. These modifications reduce self-aggregation, allowing faster absorption from subcutaneous tissue compared to regular insulin.

Pharmacokinetics: Onset ~15 minutes, peak effect ~1-1.5 hours, duration ~3-5 hours. This profile closely mimics endogenous prandial insulin secretion, making it ideal for administration immediately before or after meals (within 15 minutes).

Mechanism of action: Like all insulins, glulisine binds insulin receptors (tyrosine kinase receptors), promoting glucose uptake into skeletal muscle and adipose tissue via GLUT4 translocation, inhibiting hepatic gluconeogenesis, and promoting glycogen synthesis, lipogenesis, and protein synthesis while inhibiting lipolysis and proteolysis.

Clinical use: Used in both Type 1 and Type 2 diabetes mellitus, often in basal-bolus regimens combined with long-acting insulins (glargine, detemir) or in insulin pumps. Helps reduce postprandial hyperglycemia and HbA1c.

Adverse effects: Hypoglycemia is the primary risk, especially if dosing doesn't match carbohydrate intake. Injection site reactions, lipodystrophy with repeated injections at same site, and rare allergic reactions can occur. Weight gain is a class effect of insulin therapy.

Key teaching points for boards: Rapid-acting analogs (lispro, aspart, glulisine) should be distinguished from regular insulin (slower onset, used for IV administration in DKA) and long-acting analogs (glargine, detemir, degludec) which provide basal coverage without pronounced peaks. Understanding the pharmacokinetic profiles helps predict timing of hypoglycemic episodes and guides patient education on injection timing relative to meals.